Digital chronic care company Welldoc has received its ninth FDA 510(k) clearance for its diabetes management platform BlueStar.
The new clearance, which was announced by Welldoc Wednesday, but approved by the FDA earlier this month, expands its earlier approval for insulin dosing support to include bolus and premixed insulin titration for Type 2 diabetes.
The Insulin Adjustment Program with...
Last August -- almost a year ago now -- The New York Times reported that two insurers had agreed to pay $100 a month in reimbursement for use of WellDoc's mobile-enabled diabetes management program. The report, which sourced WellDoc's president Anand Iyer as its source, expected the payers to begin supporting the "mobile integrated therapy" in early 2013.
This morning WellDoc launched a new...
